Engineers Gate Manager LP Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Posted by Brenda Bartman on Sep 13th, 2026

Engineers Gate Manager LP purchased a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) in the second quarter, Holdings Channel.com reports. The firm purchased 16,302 shares of the company’s stock, valued at approximately $4,646,000.

Several other institutional investors have also made changes to their positions in the company. Bank of America Corp DE bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $67,657,000. Man Group plc bought a new position in BeOne Medicines during the second quarter valued at approximately $59,031,000. BNP Paribas Financial Markets acquired a new stake in BeOne Medicines in the second quarter valued at approximately $38,337,000. First Trust Advisors LP lifted its stake in BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in BeOne Medicines in the second quarter worth approximately $26,034,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO John Oyler sold 54,892 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the sale, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of BeOne Medicines stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total value of $106,400.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 613,411 shares of company stock valued at $202,729,283 in the last quarter. Insiders own 6.19% of the company’s stock.

Analyst Ratings Changes

ONC has been the topic of a number of recent research reports. Wolfe Research restated an “outperform” rating and set a $370.00 price target on shares of BeOne Medicines in a report on Monday, August 10th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Finally, TD Cowen boosted their price target on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BeOne Medicines has an average rating of “Buy” and an average price target of $402.71.

Read Our Latest Report on ONC

BeOne Medicines Price Performance

Shares of BeOne Medicines stock opened at $346.51 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $339.71 and a 200-day simple moving average of $311.50. The stock has a market capitalization of $38.04 billion, a price-to-earnings ratio of 61.01 and a beta of 0.51. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current year.

About BeOne Medicines

(Free Report)

BeOne Medicines Ltd. is a global biotechnology company focused on the discovery, development and commercialization of medicines for cancer and other serious diseases. The company works across research, clinical development, manufacturing and commercialization, with the goal of expanding access to innovative treatments in markets around the world.

BeOne’s commercial portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat certain B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy approved in multiple markets for several cancer indications.